New hope for advanced lung cancer: real-world study of sugemalimab plus chemo begins
NCT ID NCT07247227
First seen Dec 10, 2025 · Last updated May 15, 2026 · Updated 17 times
Summary
This study looks at how well a drug called sugemalimab works when combined with standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer (NSCLC). The study is happening in real-world clinics, not just research hospitals, and includes 150 adults with stage III or IV NSCLC. The main goal is to see how long it takes for the cancer to grow or for the patient to pass away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
cancer hospital， Chinese Academy of medical sciences and Peking union medical college
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.